Rho-associated coiled-coil containing protein kinase 1 (ROCK1) and Rho-associated coiled-coil containing protein kinase 2 (ROCK2) (ROCK1, ROCK2)

Rho-associated coiled-coil containing kinases 1 and 2 (ROCK1 and ROCK2) are serine/threonine protein kinases that act as major downstream effectors of Rho GTPases, especially RhoA. Both have similar structural domains: an N-terminal kinase domain, a central coiled-coil domain (containing the Rho-binding domain), and a C-terminal pleckstrin homology (PH) domain containing a cysteine-rich region. Activation occurs via binding of active GTP-bound Rho proteins to the Rho-binding domain, releasing autoinhibition and increasing kinase activity. ROCK1 and ROCK2 regulate cytoskeletal dynamics, cell contraction, motility, shape, proliferation, and apoptosis by phosphorylating myosin light chain and many cytoskeletal proteins. Both enzymes play key roles in pathological conditions such as cardiovascular, fibrotic, inflammatory, neurodegenerative diseases, and cancer, making them important therapeutic targets. Clinical and preclinical inhibitors exist, primarily as antihypertensive and anti-glaucoma agents, but their broader therapeutic potential remains under study due to safety and specificity challenges[1][3][4][5][6][7][8].

Other names

Rho kinase 1Rho kinase 2Rho-associated kinase 1Rho-associated kinase 2ROKα (for ROCK2)ROKβ (for ROCK1)ROK (family designation)Rho-kinase

Inhibition of ROCK1/ROCK2 kinase activity (blocks phosphorylation of target proteins, especially myosin light chain) Reduction in actomyosin contractility Promotion of smooth muscle relaxation Decrease in cell migration and proliferation